Isocitrate Dehydrogenase 1 (NADP+), Soluble (IDH1) Kits ELISA

Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. De plus, nous expédions IDH1 Anticorps (231) et IDH1 Protéines (17) et beaucoup plus de produits pour cette protéine.

list all ELISA KIts Gène GeneID UniProt
IDH1 3417 O75874
IDH1 15926 O88844
IDH1 24479 P41562
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne

Top IDH1 Kits ELISA sur

Showing 7 out of 19 products:

Catalogue No. Reactivité Sensibilité Gamme Images Quantité Livraison Prix Détails
Humain 0.33 ng/mL 0.78 ng/mL - 50 ng/mL Typical standard curve 96 Tests 12 to 14 Days
Rat 1.35 ng/mL 3.12 ng/mL - 200 ng/mL 96 Tests 13 to 16 Days
Humain 0.28 ng/mL 0.69 ng/mL - 500 ng/mL 96 Tests 13 to 16 Days
Rat < 1.35 ng/mL 3.12 ng/mL - 200 ng/mL   96 Tests 11 to 18 Days
  96 Tests 11 to 18 Days
Boeuf (Vache)
  96 Tests 15 to 18 Days
  96 Tests 15 to 18 Days

IDH1 Kits ELISA mieux référencés

  1. Human IDH1 Kit ELISA pour Sandwich ELISA - ABIN6574327 : Tan, Jiang, Sun, Chen, Lv, Shao, Li, Qiu, Gao, Li, Tan, Zhou, Wang, Ding, Wang, Sun, Hang, Shi, Feng, He, He: Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis. dans Molecular & cellular proteomics : MCP 2012 (PubMed)
    Show all 4 Pubmed References

Plus Kits ELISA pour IDH1 partenaires d'interaction

Human Isocitrate Dehydrogenase 1 (NADP+), Soluble (IDH1) interaction partners

  1. IDH1/2(MUT) inhibitors protected against these treatments.

  2. Within IDH1-wildtype glioblastoma tumors, the subtypes revealed different survival (p < 0.001), thereby highlighting the synergistic consideration of molecular and imaging measures for prognostication.

  3. Results find the prevalence of the IDH1105GGT SNP considerably higher in patients with brain tumors compared to the control population. IDH1(105GGT) was more frequent in grade III tumors compared to grade II and grade IV. IDH1 (105GGT) was more frequent in grade II and III tumors without an IDH tumor missense mutation than in those with. The IDH1(105GGT) SNP likely represents an important genetic marker in brain tumors.

  4. Authors describe a biosynthetic pathway exhibited by cells expressing mutant IDH1. By virtue of a change in cellular redox homeostasis, IDH1-mutated cells synthesize excess glutamine-derived proline through enhanced activity of pyrroline 5-carboxylate reductase 1 (PYCR1), coupled to NADH oxidation.

  5. Although brain tumor patients with IDH1 mutation are at very low risk of venous thromboembolism, the risk of VTE in patients with IDH1 wild-type tumors is strongly linked to podoplanin expression levels.

  6. Detection of IDH1 and IDH2 Mutation in Formalin-fixed Paraffin-embedded Gliomas Using Allele-specific COLD-PCR and Probe Melting Curve Analysis.

  7. noninvasive determination of the IDH mutation status of a presumed glioma by means of MRS may be incorporated into a routine diagnostic imaging protocol and can be used to obtain additional information for patient care

  8. World Health Organization classification of brain tumors introduced isocitrate dehydrogenase genotype and epigenetic 1p/19q codeletion as two key molecular markers.

  9. IDH1 mutation is an independent factor for longer overall survival and progression free survival in glioblastoma multiforme patients when compared to wild-type IDH1 (review).

  10. IDH1-R132 changes are associated with NPM1 and other mutations status in acute myeloid leukemia.

  11. IDH1(R132C) mutation was relatively prevalent in intrahepatic cholangiocarcinoma; IDH1R132C mutation was involved with downregulated genes with hypermethylation status

  12. These results indicated that mutation of IDH1 aggravated the fatty acidinduced oxidative stress in HCT116 cells, by suppressing FAO and disrupting the mitochondrial respiratory chain. The results of the present study may provide novel insight into therapeutic strategies for the treatment of cancer types with IDH mutation.

  13. The overexpression of total and phosphorylated mTOR as well as phosphorylated rpS6 (residues 240-244) were associated with wild-type IDH1 only glioblastomas. The expression and phosphorylation of mTOR and phosphorylation of rpS6 at residues 240-244 were associated with a worse prognosis in glioblastomas.

  14. Fibulin-5 silencing in non-small-cell lung cancer cells is due to the hypermethylation of its promoter through 2-hydroxyglutarate, production of which arises from a mutation in IDH1.

  15. combined expression of Jak2V617F and mutant IDH1R132H or Idh2R140Q induces myeloproliferative neoplasm progression, alters stem/progenitor cell function, and impairs differentiation

  16. IDH1 mutation causing metabolic stress is associated with glioma.

  17. IDH1 mutation is associated with minimal residual disease assessment in acute myeloid leukemia.

  18. Heterozygous IDH1 (R132H) suppresses but hemizygous IDH1 (R132H) promotes anchorage-independent growth. Whereas genetic deletion of the wild-type allele in IDH1 (R132H) -heterozygous cells resulted in a pronounced increase in neurosphere genesis, restoration of IDH1 expression in IDH1 (R132H) -hemizygous cells led to the contrary.

  19. Alterations of EZH2, KMT2C, and CHD4 at genetic level or protein level could perturb epigenetic program, leading to malignant transformation in glioma.

  20. In most cases, IDH1, TP53 and TERTp mutation status and MGMT and ATRX protein expression levels were stable during recurrence, which may indicate that these alterations occurred early in astrocytic tumour development.

Mouse (Murine) Isocitrate Dehydrogenase 1 (NADP+), Soluble (IDH1) interaction partners

  1. combined expression of Jak2V617F and mutant IDH1R132H or Idh2R140Q induces myeloproliferative neoplasm progression, alters stem/progenitor cell function, and impairs differentiation

  2. Vitamin C treatment induced an IDH1(R132H)-dependent reduction in cell proliferation.

  3. IDH1 expression regulates TCA cycle in glioma and affects glioma cell growth.GDH2 promotes growth of IDH1-expressing gliomas.

  4. Through the use of a conditional mutant mouse model that confers a less aggressive tumor phenotype, findings provide new insight into the effects of mutant Idh1 on a candidate cell of origin for glioma, mutant Idh1's role in disrupting the microenvironment from which gliomas arise, and mutant Idh1's effect on the course of glioma progression.

  5. IDH1 mutations caused down-regulation of leukocyte chemotaxis, resulting in repression of the tumor-associated immune system.

  6. Idh1(R132H) mutation in the major adult neurogenic stem cell niche causes a phenotype resembling gliomagenesis

  7. Mutant IDH1 downregulates the DNA damage (DD) sensor ATM by altering histone methylation, leading to impaired DNA repair, increased sensitivity to DD, and reduced HSC self-renewal, independent of TET2.

  8. Using whole RNA sequencing of bone marrow cells in iron-overloaded mice, it was observed that Idh1 and Aco1, enzymes involved in the TCA cycle, were elevated.

  9. data suggest that mutant IDH1 contributes to malignancy in the T-cell lineage and may alter the metabolic profile of malignant T cells

  10. The results suggest that Idh1 has a physiological function in protecting cells from oxidative stress by regulating the intracellular NADP(+)/NADPH ratio.

  11. These results support the translational potential of immunotherapeutic targeting of gliomas carrying IDH1 mutations R132H.

  12. MiR-181a regulates lipid metabolism via IDH1

  13. revealed a role for IDH1 in the synthesis/turnover of phospholipids in developing astrocytes and highlight the lipid alterations resulting from the loss of wild-type IDH1 activity.

  14. these data show that mutant IDH or d-2HG causes persistence of chondrocytes, giving rise to rests of growth-plate cells that persist in the bone as enchondromas.

  15. WA might exert its chemopreventive activity via inhibiting not only oncogenic activation, but also IDH1 inactivation.

  16. Brain-specific Idh1-KI mice show brain hemorrhage accompanied by high D2HG levels but decreased ROS

  17. Suggest that decreased IDPc expression renders melanocytes more vulnerable to oxidative stress, and IDPc plays an important antioxidant function in melanocytes.

  18. Absence of IDH1 mutations in low-grade gliomas (LGGs) identifies a novel entity of LGGs with distinctive location, infiltrative behavior, specific molecular alterations, and dismal outcome.

  19. a possible association between IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia.

  20. IDPc would be a major NADPH producer required for fat and cholesterol synthesis.

Cow (Bovine) Isocitrate Dehydrogenase 1 (NADP+), Soluble (IDH1) interaction partners

  1. Data suggest that the expression of cytosolic NADP+-dependent isocitrate dehydrogenase in bovine mammary epithelium is modulated by regulators of differentiation including extracellular matrix and lactogenic hormones as well as metabolic effectors.

Zebrafish Isocitrate Dehydrogenase 1 (NADP+), Soluble (IDH1) interaction partners

  1. generated a transgenic zebrafish model system for mutations in IDH1 that can be used for functional analysis and drug screening. Our model systems help understand the biology of IDH1 mutations and its role in tumor formation.

IDH1 profil antigène

Antigen Summary

Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD(+) as the electron acceptor and the other NADP(+). Five isocitrate dehydrogenases have been reported: three NAD(+)-dependent isocitrate dehydrogenases, which localize to the mitochondrial matrix, and two NADP(+)-dependent isocitrate dehydrogenases, one of which is mitochondrial and the other predominantly cytosolic. Each NADP(+)-dependent isozyme is a homodimer. The protein encoded by this gene is the NADP(+)-dependent isocitrate dehydrogenase found in the cytoplasm and peroxisomes. It contains the PTS-1 peroxisomal targeting signal sequence. The presence of this enzyme in peroxisomes suggests roles in the regeneration of NADPH for intraperoxisomal reductions, such as the conversion of 2, 4-dienoyl-CoAs to 3-enoyl-CoAs, as well as in peroxisomal reactions that consume 2-oxoglutarate, namely the alpha-hydroxylation of phytanic acid. The cytoplasmic enzyme serves a significant role in cytoplasmic NADPH production.

Gene names and symbols associated with IDH1

  • isocitrate dehydrogenase (NADP(+)) 1, cytosolic (IDH1) anticorps
  • isocitrate dehydrogenase 1 (NADP+), soluble (Idh1) anticorps
  • isocitrate dehydrogenase (NADP(+)) 1, cytosolic (Idh1) anticorps
  • isocitrate dehydrogenase 1 (NADP+) L homeolog (idh1.L) anticorps
  • isocitrate dehydrogenase 1 (NADP+), soluble (idh1) anticorps
  • AI314845 anticorps
  • AI788952 anticorps
  • cb876 anticorps
  • E030024J03Rik anticorps
  • fm90e09 anticorps
  • Id-1 anticorps
  • IDCD anticorps
  • IDH anticorps
  • Idh-1 anticorps
  • IDP anticorps
  • Idpc anticorps
  • im:7143416 anticorps
  • NADP-CICDH anticorps
  • PICD anticorps
  • wu:fm90e09 anticorps

Protein level used designations for IDH1

NADP(+)-specific ICDH , NADP-dependent isocitrate dehydrogenase, cytosolic , NADP-dependent isocitrate dehydrogenase, peroxisomal , isocitrate dehydrogenase [NADP] cytoplasmic , oxalosuccinate decarboxylase , IDH , IDP , cytosolic NADP-isocitrate dehydrogenase , isocitrate dehydrogenase 1 (NADP+), soluble , isocitrate dehydrogenase [NADP] cytoplasmic-like , Isocitrate dehydrogenase 1, soluble , isocitrate dehydrogenase 1

3417 Homo sapiens
443257 Ovis aries
751618 Felis catus
100414768 Callithrix jacchus
15926 Mus musculus
24479 Rattus norvegicus
494713 Xenopus laevis
281235 Bos taurus
100328559 Oryctolagus cuniculus
478889 Canis lupus familiaris
100006589 Danio rerio
100729107 Cavia porcellus
100066416 Equus caballus
Fournisseurs de qualité sélectionnés pour IDH1 (IDH1) Kits ELISA
Avez-vous cherché autre chose?